Peak Retirement Planning Inc. Acquires Shares of 10,238 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peak Retirement Planning Inc. bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,238 shares of the medical equipment provider's stock, valued at approximately $917,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its stake in Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after buying an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its stake in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after buying an additional 30,891 shares during the last quarter. Finally, Swedbank AB raised its stake in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after buying an additional 385,000 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. Corporate insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the subject of several analyst reports. B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Truist Financial reduced their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus presently has a consensus rating of "Buy" and a consensus target price of $132.67.

Lantheus Stock Down 2.1%

LNTH stock traded down $1.58 during trading on Wednesday, reaching $74.18. The company's stock had a trading volume of 839,315 shares, compared to its average volume of 987,749. Lantheus Holdings, Inc. has a 1 year low of $73.11 and a 1 year high of $126.89. The company has a market capitalization of $5.13 billion, a P/E ratio of 12.34 and a beta of 0.23. The company's fifty day moving average is $93.51 and its 200-day moving average is $91.90.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the previous year, the company posted $1.69 EPS. The company's quarterly revenue was up .8% on a year-over-year basis. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.